About Human Metabotropic Glutamate Receptor 2 (GRM2/mGluR2) Stable Cell Line

Metabotropic Glutamate Receptor 2 (GRM2), commonly known as mGluR2, is a Class C G protein-coupled receptor (GPCR) that belongs to the group II metabotropic glutamate receptor family, together with mGluR3 (GRM3). GRM2 is activated by the neurotransmitter glutamate, the principal excitatory neurotransmitter in the central nervous system. Unlike ionotropic glutamate receptors that mediate rapid synaptic transmission, GRM2 modulates neuronal activity through slower intracellular signaling mechanisms. Upon activation, GRM2 primarily couples to Gi/o proteins, resulting in inhibition of adenylate cyclase activity, decreased intracellular cAMP levels, modulation of ion channels, and suppression of neurotransmitter release.

GRM2 is widely expressed throughout the brain, including the cerebral cortex, hippocampus, amygdala, thalamus, and other regions involved in cognition, emotion, sensory processing, and synaptic plasticity. The receptor functions as an important presynaptic regulator that limits excessive glutamate release and helps maintain excitatory-inhibitory balance within neuronal circuits. Dysregulation of GRM2 signaling has been implicated in schizophrenia, anxiety disorders, depression, addiction, epilepsy, chronic pain, and neurodegenerative diseases. As a result, GRM2 has emerged as an attractive therapeutic target for the treatment of multiple neurological and psychiatric disorders.

eEnzyme's Human GRM2 Stable Cell Line provides a reliable and reproducible cellular platform for investigating mGluR2-mediated signaling pathways and evaluating receptor-targeted therapeutics. The cell line enables quantitative assessment of agonists, antagonists, positive allosteric modulators (PAMs), negative allosteric modulators (NAMs), and novel glutamatergic compounds through cAMP assays, reporter gene assays, calcium signaling assays, and other GPCR functional screening platforms. Researchers can utilize this stable cell line for receptor characterization, ligand profiling, potency determination, lead optimization, and high-throughput screening applications supporting neuroscience and neuropsychiatric drug discovery programs.

Applications of the GRM2 Stable Cell Line

• GRM2 (mGluR2) receptor pharmacology studies
• Glutamate signaling investigations
• Agonist, antagonist, PAM, and NAM screening
• Schizophrenia and psychiatric disorder research
• Anxiety and depression studies
• Epilepsy and neurodegenerative disease research
• cAMP and GPCR functional assays
• High-throughput screening applications

Biological Significance of GRM2

GRM2 is a critical regulator of glutamatergic neurotransmission and neuronal network stability. Activation of mGluR2 suppresses presynaptic glutamate release and modulates synaptic signaling pathways that influence cognition, learning, memory, emotional processing, and sensory perception. Through its inhibitory effects on excitatory neurotransmission, GRM2 helps protect neurons from excitotoxicity and maintains proper neuronal circuit function. The receptor has attracted significant attention as a therapeutic target for schizophrenia, anxiety, depression, substance use disorders, and chronic pain due to its ability to modulate glutamatergic signaling without directly blocking neurotransmission. In addition, GRM2-selective allosteric modulators have shown promise in preclinical and clinical studies targeting central nervous system disorders. Because of its central role in regulating excitatory neurotransmission and brain function, GRM2 remains an important target in neuroscience research and CNS drug discovery. The GRM2 Stable Cell Line provides a valuable tool for studying glutamate receptor biology and advancing the development of next-generation neuropsychiatric therapeutics.